Real-world study on the efficacy and safety of first-line antiviral therapy for chronic hepatitis B
10.3760/cma.j.cn501113-20230322-00124
- VernacularTitle:慢性乙型肝炎一线抗病毒药物治疗效果及其安全性的真实世界研究
- Author:
Chudi CHANG
1
;
Chen DONG
;
Suxian ZHAO
;
Xiwei YUAN
;
Xiaoxiao ZHANG
;
Dandan ZHAO
;
Yao DOU
;
Yuemin NAN
Author Information
1. 河北医科大学第三医院中西医结合肝病科 河北省慢性肝病肝纤维化机制研究重点实验室，石家庄 050051
- Keywords:
Chronic hepatitis B;
Efficacy;
Safety;
Tenofovir alafenamide fumarate;
Tenofovir disoproxil fumarate;
Entecavir
- From:
Chinese Journal of Hepatology
2023;31(8):855-861
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To clarify the clinical efficacy of first-line oral antiviral drugs tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), and entecavir (ETV) in the treatment of chronic hepatitis B (CHB) and their safety profiles with lipid, bone, and kidney metabolism.Methods:458 CHB cases diagnosed and treated at the Department of Hepatology of Integrated Traditional Chinese and Western Medicine of the Third Hospital of Hebei Medical University from February 2010 to November 2022 were selected. TAF (175 cases), TDF (124 cases), and ETV (159 cases) were used as therapies. At 24 and 48 weeks, the virology, biochemical response, changes in liver stiffness measurement (LSM), and bone, kidney, and blood lipid metabolism safety profiles were compared and analyzed.Results:After 24 and 48 weeks of TAF, TDF, and ETV therapy, HBV DNA load decreased by 3.28, 2.69, and 3.14 log10 IU/ml and 3.28, 2.83, and 3.65 log10 IU/ml, respectively, compared with the baseline, and the differences between the three groups were statistically significant, P < 0.001. The complete virological response rates were 73.95%, 66.09%, 67.19%, and 82.22%, 72.48%, and 70.49%, respectively. The incidence rates of low-level viremia were 16.67%, 21.70%, and 23.08%, while poor response rates were 1.11%, 3.67%, and 4.10%. ALT normalization rates were 64.00%, 63.89%, 67.96%, and 85.33%, 80.56%, 78.64%, respectively, and there was no statistically significant difference among the groups. LSM was significantly improved in patients treated with TAF for 48 weeks, P = 0.022. Serum phosphorus level gradually decreased with the prolongation of TDF treatment. The TAF treatment group had a good safety profile for kidney, bone, and phosphorus metabolism, with no dyslipidemia or related occurrences of risk. Conclusion:There are some differences in the therapeutic effects of first-line anti-HBV drugs. TAF has the lowest incidence of low-level viremia after 48 weeks of treatment and has a good safety profile in kidney, bone, and blood lipid metabolism.
